Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
51 hedge funds and large institutions have $70.4M invested in Eiger BioPharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
17% more capital invested
Capital invested by funds: $60.4M → $70.4M (+$10M)
9% more funds holding
Funds holding: 47 → 51 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$385K |
| 2 |
PA
Perceptive Advisors
New York
|
+$339K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$246K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$162K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$1.46M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$608K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$211K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$67K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.06K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BOTOTLSJU
51
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
| – | -$1.46M | -3,635 | Closed |
|
|
AIM
52
Acrospire Investment Management
Chicago,
Illinois
| – | -$67K | -168 | Closed |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| – | -$2K | -5 | Closed |
|
54
Barclays
London,
United Kingdom
| – | -$366 | -1 | Closed |
|
EIGR Hedge Fund Activity: Q4 2016 in Review
51 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2016, worth a combined $70.4M — up 17% from $60.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EIGR positions and 4 closed out — a net gain of 5 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $385K. The largest seller was Board of Trustees of The Leland Stanford Junior University, exiting entirely with an estimated $1.46M sold.
- 51 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2016, up from 47 in Q3 2016.
- Funds reported $70.4M of Eiger BioPharmaceuticals, Inc. stock for Q4 2016, up 17% quarter-over-quarter.
- 9 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2016 and 4 closed out, a net change of +5 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2016 was Monashee Investment Management, an estimated $385K added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2016 was Board of Trustees of The Leland Stanford Junior University, an estimated $1.46M sold.
Based on aggregated 13F filings for Q4 2016.